Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/22173Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Makariou, S. E. | en |
| dc.contributor.author | Liberopoulos, E. N. | en |
| dc.contributor.author | Agouridis, A. P. | en |
| dc.contributor.author | Challa, A. | en |
| dc.contributor.author | Elisaf, M. S. | en |
| dc.date.accessioned | 2015-11-24T19:22:34Z | - |
| dc.date.available | 2015-11-24T19:22:34Z | - |
| dc.identifier.issn | 1940-4034 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/22173 | - |
| dc.rights | Default Licence | - |
| dc.title | Effect of Rosuvastatin Monotherapy and in Combination With Fenofibrate or Omega-3 Fatty Acids on Serum Vitamin D Levels | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | 10.1177/1074248412439470 | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/22431864 | - |
| heal.identifier.secondary | http://cpt.sagepub.com/content/early/2012/03/15/1074248412439470.full.pdf | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2012 | - |
| heal.abstract | Background: Low levels of 25(OH) vitamin D [25(OH)VitD] have been recognized as a new cardiovascular disease (CVD) risk factor. Statins seem to increase 25(OH)VitD concentration. Aim: To investigate whether combined treatment with the usual dose of rosuvastatin plus fenofibrate or omega-3 fatty acids would increase 25(OH)VitD levels compared with the high-dose rosuvastatin monotherapy in participants with mixed dislipidemia. Methods: We randomly allocated 60 patients with mixed dyslipidemia (low-density lipoprotein cholesterol: >160 mg/dL plus triglycerides: >200 mg/dL) to receive rosuvastatin 40 mg (n = 22), rosuvastatin 10 mg plus fenofibrate 200 mg (n = 21), or rosuvastatin 10 mg plus omega-3 fatty acids 2 g (n = 17) daily for 3 months. Our primary end point was changes in the levels of serum 25(OH)VitD. Results: Rosuvastatin monotherapy was associated with a 53% increase in 25(OH)VitD (from 14.6 [1.0-38.0] to 17.8 [5.3-49.6] ng/mL; P = .000). Rosuvastatin plus micronized fenofibrate and rosuvastatin plus omega-3 fatty acids were associated with increases of 64% (from 14.1 [1.0-48.0] to 18.4 [6.7-52.4] ng/mL, P = .001) and 61% (from 10.4 [6.6-38.4] to 14.0 [9.6-37.6] ng/mL, P = .04), respectively. The changes in 25(OH)VitD after treatment were comparable in the 3 groups. Conclusion: High-dose rosuvastatin monotherapy and the usual dose of rosuvastatin plus fenofibrate or omega-3 fatty acids are associated with significant and similar increases in the 25(OH)VitD levels. This increase may be relevant in terms of CVD risk prevention. | en |
| heal.journalName | J Cardiovasc Pharmacol Ther | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Makariou-2012-Effect of Rosuvastat.pdf | 135.91 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
